Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

BCMA-targeted CAR-T immunotherapy

DRUG CLASS:

BCMA-targeted CAR-T immunotherapy

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	ciltacabtagene autoleucel Sensitive: A1 - Approval J&J Press Release - 6 days (New A1) ciltacabtagene autoleucel Sensitive : A1 J&J Press Release - 6d	ciltacabtagene autoleucel Sensitive: A1 - Approval J&J Press Release - 6 days ciltacabtagene autoleucel Sensitive : A1 J&J Press Release - 6 days - (New A1)
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	idecabtagene vicleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks (New A1) idecabtagene vicleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3wk	idecabtagene vicleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks idecabtagene vicleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3 weeks - (New A1)
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	PBCAR269A Sensitive: B - Late Trials PBCAR269A Sensitive : B	PBCAR269A Sensitive: B - Late Trials PBCAR269A Sensitive : B
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	ALLO-715 Sensitive: B - Late Trials ALLO-715 Sensitive : B	ALLO-715 Sensitive: B - Late Trials ALLO-715 Sensitive : B
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	ALLO-605 Sensitive: B - Late Trials ALLO-605 Sensitive : B	ALLO-605 Sensitive: B - Late Trials ALLO-605 Sensitive : B
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	equecabtagene autoleucel Sensitive: B - Late Trials equecabtagene autoleucel Sensitive : B	equecabtagene autoleucel Sensitive: B - Late Trials equecabtagene autoleucel Sensitive : B
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	CB-011 Sensitive: B - Late Trials CB-011 Sensitive : B	CB-011 Sensitive: B - Late Trials CB-011 Sensitive : B
IL7R overexpression	Multiple Myeloma	IL7R overexpression	Multiple Myeloma	bb21217 Sensitive: C3 – Early Trials bb21217 Sensitive : C3	bb21217 Sensitive: C3 – Early Trials bb21217 Sensitive : C3
TNFRSF17 overexpression	Multiple Myeloma	TNFRSF17 overexpression	Multiple Myeloma	ciltacabtagene autoleucel Sensitive: C3 – Early Trials ciltacabtagene autoleucel Sensitive : C3	ciltacabtagene autoleucel Sensitive: C3 – Early Trials ciltacabtagene autoleucel Sensitive : C3
CD19 expression + TNFRSF17 expression	Diffuse Large B Cell Lymphoma	CD19 expression + TNFRSF17 expression	Diffuse Large B Cell Lymphoma	GC012F Sensitive: C3 – Early Trials GC012F Sensitive : C3	GC012F Sensitive: C3 – Early Trials GC012F Sensitive : C3
TNFRSF17 deletion	Multiple Myeloma	TNFRSF17 deletion	Multiple Myeloma	idecabtagene vicleucel Resistant: C4 – Case Studies idecabtagene vicleucel Resistant : C4	idecabtagene vicleucel Resistant: C4 – Case Studies idecabtagene vicleucel Resistant : C4
TNFRSF17 expression	Multiple Myeloma	TNFRSF17 expression	Multiple Myeloma	ACLX-001 Sensitive: D – Preclinical ACLX-001 Sensitive : D	ACLX-001 Sensitive: D – Preclinical ACLX-001 Sensitive : D
B2M-HLA-E fusion	Multiple Myeloma	B2M-HLA-E fusion	Multiple Myeloma	CB-011 Sensitive: D – Preclinical CB-011 Sensitive : D	CB-011 Sensitive: D – Preclinical CB-011 Sensitive : D
CD47 overexpression	Multiple Myeloma	CD47 overexpression	Multiple Myeloma	BCMA-targeted CAR-T immunotherapy Sensitive: D – Preclinical BCMA-targeted CAR-T immunotherapy Sensitive : D	BCMA-targeted CAR-T immunotherapy Sensitive: D – Preclinical BCMA-targeted CAR-T immunotherapy Sensitive : D